Proprietary methodologies across four validated research domains, each designed to close the diagnostic gap in oncology.
Development and optimization of methodologies for the isolation, identification, and characterization of circulating tumor cells associated with clinically significant malignancies.
Advancement of proprietary imaging systems designed to enhance signal detection and cellular resolution beyond conventional diagnostic approaches.
Integration of molecular biomarkers to improve specificity, risk stratification, and clinical interpretability of diagnostic results.
Development and optimization of methodologies for the isolation, identification, and characterization of circulating tumor cells associated with clinically significant malignancies.
Advancing Evidence-Based Precision Diagnostics. 5Q Spectra Corporation is committed to the development of clinically validated diagnostic technologies supported by rigorous scientific research. Our work integrates translational oncology, molecular biology, and computational analytics to advance early cancer detection and improve patient outcomes. Our research program is designed to meet the standards expected of high-complexity clinical laboratory testing and to support adoption across clinical, academic, and regulatory environments.
Analytical validation of ProstateDx™ assay performance under CLIA conditions Clinical utility analysis in pre-biopsy patient populations Integration of imaging and molecular data for enhanced diagnostic accuracy
5Q Spectra’s diagnostic assays are developed and validated in accordance with established clinical laboratory standards, including:
Analytical validation (precision, reproducibility, limit of detection) Clinical validation (sensitivity, specificity, AUC-ROC) Workflow standardization across laboratory environments Quality control and assay reproducibility across operators and sites
Our research is conducted in collaboration with clinical investigators, laboratory scientists, and academic partners with expertise in oncology, pathology, and translational medicine. The company’s scientific leadership includes experienced clinicians and researchers with backgrounds in oncology, laboratory medicine, and computational biology, ensuring that all research is grounded in clinical relevance and real-world applicability.
5Q Spectra adheres to principles of scientific rigor, transparency, and reproducibility. Data generated through our research programs are intended to support clinical adoption, inform healthcare providers, and contribute to the broader scientific community.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.
Publications and research findings presented on this page may include preliminary data and are subject to ongoing validation. Clinical decisions should be made in conjunction with established diagnostic standards and physician judgment.
For full-text articles, reprints, or additional scientific information, please contact Scientific Affairs at 5Q Spectra Corporation.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.